|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.09.26 - 11:30
|
Hong Kong targets biomedicine powerhouse status in debut five-year plan (SCMP)
|
|
|
Biomedicine is set to feature in Hong Kong's first five-year plan, due to be unveiled next week, as the city's top officials signal closer medical cooperation across the Greater Bay Area.
Lending weight to those ambitions, global pharmaceutical company GSK emphasised its interest in expanding its role in the region's biotech development on Wednesday, at the fifth Hong Kong International Biotechnology Conference and Exhibition (BIOHK).
Speaking at the event, Hong Kong Secretary for Health Lo......
|
|
|
|
|
09.09.26 - 08:12
|
GSK Sector Perform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat GSK mit "Sector Perform" und einem Kursziel von 1975 Pence in die Bewertung aufgenommen. Eine gute Kursentwicklung im vergangenen Jahr spiegele die verbesserte Fundamentallage und eine positive ......
|
|
|
08.09.26 - 09:12
|
GSK Underweight (DPA-AFX)
|
|
|
LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für GSK von 1900 auf 1800 Pence gesenkt und die Einstufung auf "Underweight" belassen. Analyst James Gordon warf am Montag einen detaillierten Blick auf die europäische ......
|
|
|
|
|
|
|
|
|
|
|
04.09.26 - 05:30
|
Research: Citi Lifts HUTCHMED TP to HKD39, Reiterates Buy/High Risk Rating (AAStocks)
|
|
|
HUTCHMED (00013.HK) and GSK sealed a licensing deal for HMPL-A830 (KRAS-EGFR ATTC). In a research report, Citi said GSK's endorsement validated the ATTC platform concept, and the deal was reached earlier than the broker had expected.Citi expected first patient dosing for HMPL-A251 and HMPL-A580 from end-2026 to early 2027, w......
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
